Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
I-131 MIBG targeted radiotherapy for malignant neuroendocrine tumors
jRCTs041180040Completed
- Start
- Sep 2009
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Open-label, single-arm trial of Iobenguane I-131 in apudoma (NET). Primary endpoints: Anti-tumor effects, Prognosis and 1 more. Started Sep 2009; status: completed.
02
Drugs
Iobenguane I-131
03
Conditions
apudoma (NET)
Beyond the preview
Go deeper on jRCTs041180040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041180040.